The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.15 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing digital health and telemedicine, growing adoption of targeted therapy, improved diagnostic tools, growing awareness of progressive multifocal leukoencephalopathy (pml). Major trends in the forecast period include technological advancements in progressive multifocal leukoencephalopathy (pml) treatment, research and clinical trials, early diagnosis and screening, development of new drug therapies.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report
Scope Of Progressive Multifocal Leukoencephalopathy Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Progressive Multifocal Leukoencephalopathy Treatment Market Overview
Market Drivers –
The growing prevalence of human immunodeficiency virus (HIV) infection is expected to propel the growth of the progressive multifocal leukoencephalopathy market going forward. HIV is a retrovirus that attacks the immune system, specifically targeting CD4 cells (also known as T cells), which play a crucial role in helping the body fight infections. Most patients with HIV infection develop PML due to a poor immunological condition indicated by a low CD4 cell count (200/L), the single most significant cause of PML cases worldwide. When a severe HIV-related immune deficit arises, the latent JCV archetype strain in the brain may increase, leading to brain white matter lesions and PML. For instance, in December 2022, according to the Joint United Nations Programme on HIV and AIDS (UNAIDS), a Switzerland-based joint venture of the United Nations for AIDS, 630,000 (480,000–880,000) people died from AIDS-related illnesses and there were 39.0 million [33.1 million–45.7 million] people living with HIV globally. In 2022, 1.3 million [1 million–1.7 million] additional people developed HIV for the first time. Therefore, the growing prevalence of human immunodeficiency virus (HIV) infection is driving the growth of the progressive multifocal leukoencephalopathy market.
Market Trends –
Major companies operating in the advanced multifocal leukoencephalopathy treatment market are increasingly focusing on product innovation to provide reliable products to their customers and to strengthen their market position. For instance, in October 2022, Cellevolve Bio, a US-based clinical company, received FDA (The United States Food and Drug Administration) clearance for an investigational new drug (IND) application and orphan drug designation for CE-VST01-JC. This drug aims to treat progressive multifocal leukoencephalopathy and will be evaluated in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial called ASCEND-JC. The problem seeks to compare CE-VST01-JC to a placebo to see if CE-VST01-JC can decrease or prevent neurological progression in PML patients. CE-VST01-JC is a T-cell therapy that targets the JC virus, the cause of PML. It is a significant moment for the PML community and Cellevolve, as the most considerable cell treatment study in PML history will be ASCEND-JC.
The progressive multifocal leukoencephalopathy treatment market covered in this report is segmented –
1) By Treatment: Anti-retroviral Therapy; Antiviral Or Anti-John Cunningham Virus (JCV); Other Symptomatic
2) By Indication: HIV Or AIDS; Organ Transplantation; Multiple Sclerosis; Hematologic Malignancies
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
Get an inside scoop of the progressive multifocal leukoencephalopathy treatment market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=12864&type=smp
Regional Insights –
North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2023. The regions covered in the progressive multifocal leukoencephalopathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Acorda Therapeutics, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Ipsen Pharma, Apotex Inc., Alkermes PLC, Alnylam Pharmaceuticals Inc., Genentech Inc., Karyopharm Therapeutics Inc., ARIAD Pharmaceuticals Inc., Spectrum Pharmaceuticals, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc.
Table of Contents
1. Executive Summary
2. Progressive Multifocal Leukoencephalopathy Treatment Market Report Structure
3. Progressive Multifocal Leukoencephalopathy Treatment Market Trends And Strategies
4. Progressive Multifocal Leukoencephalopathy Treatment Market – Macro Economic Scenario
5. Progressive Multifocal Leukoencephalopathy Treatment Market Size And Growth
…..
27. Progressive Multifocal Leukoencephalopathy Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Read Related Topics:
https://goodprnews.com/small-cell-lung-cancer-therapeutics-market-size/
https://goodprnews.com/congenital-diaphragmatic-hernia-drugs-market-size/
https://goodprnews.com/reversible-airway-diseases-treatment-market-size/
https://topprnews.com/small-cell-lung-cancer-therapeutics-market-share/
https://topprnews.com/congenital-diaphragmatic-hernia-drugs-market-share/
https://topprnews.com/reversible-airway-diseases-treatment-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
